GTx, Inc.  

(Public, NASDAQ:GTXI)   Watch this stock  
Find more results for Diane Young
0.874
+0.044 (5.30%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.83 - 0.94
52 week 0.41 - 1.59
Open 0.88
Vol / Avg. 35,351.00/81,830.00
Mkt cap 122.69M
P/E     -
Div/yield     -
EPS -0.56
Shares 140.37M
Beta 1.88
Inst. own 10%
Nov 9, 2015
Q3 2015 GTX Inc Earnings Release (Estimated) Add to calendar
Aug 6, 2015
Q2 2015 GTX Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 GTX Inc Earnings Release
Jun 2, 2015
GTX Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -438.91% -118.97%
Return on average equity - -276.44%
Employees 25 -
CDP Score - -

Address

175 Toyota Plz Fl 7
MEMPHIS, TN 38103-5601
United States - Map
+1-901-5239700 (Phone)
+1-901-8448075 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). As of December 31, 2014, the Company's lead product candidate, Enobosarm (GTx-024), for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer and for the treatment of women with estrogen receptor (ER) positive and AR positive advanced breast cancer, was in Phase II clinical development stage. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer (CRPC).

Officers and directors

Robert James Wills Ph.D. Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Marc S. Hanover Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jason T. Shackelford Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Henry P. Doggrell Sr. Vice President, Chief Legal Officer, Secretary
Age: 66
Bio & Compensation  - Reuters
Diane C Young M.D. Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Joseph R. Hyde III Lead Director
Age: 71
Bio & Compensation  - Reuters
Michael G. Carter M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
J. Kenneth Glass Independent Director
Age: 68
Bio & Compensation  - Reuters
Kenneth S. Robinson M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters